Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

The United States is home to one of the leading healthcare systems globally, primarily due to its remarkable ability to drive ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential blockbuster cancer drug developed by Genentech Inc. and parent company ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline ...

Genentech disclosed in regulatory filings this week that it will lay off 436 employees at its South San Francisco ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

https://www.tipranks.com/news/the-fly/stryker-price-target-raised-to-400-from-360-at-canaccord Genentech, a member of the Roche (RHHBY), announced topline one-year ...